Is BMEA or VTGN more profitable?

VistaGen Therapeutics' return on equity of -109.72% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% VistaGen Therapeutics N/A -109.72% -89.62%

Is VTGN or PMN more profitable?

VistaGen Therapeutics' return on equity of -109.72% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets VistaGen Therapeutics N/A -109.72% -89.62% Promis Neurosciences N/A -237.99% -151.04%

VistaGen Therapeutics (VTGN) Competitors

$0.54 -0.01 (-1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$0.54 0.00 (-0.04%)

As of 04:41 PM Eastern

Compare

VTGN vs. BMEA, LFVN, VRCA, PMN, and FTLF

Should you buy VistaGen Therapeutics stock or one of its competitors? MarketBeat compares VistaGen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VistaGen Therapeutics include Biomea Fusion (BMEA), Lifevantage (LFVN), Verrica Pharmaceuticals (VRCA), Promis Neurosciences (PMN), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry.

How does VistaGen Therapeutics compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Biomea Fusion has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Biomea Fusion had 4 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 0 mentions for VistaGen Therapeutics. Biomea Fusion's average media sentiment score of 0.50 beat VistaGen Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Overall Sentiment
Biomea Fusion	Neutral
VistaGen Therapeutics	Neutral

VistaGen Therapeutics' return on equity of -109.72% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
VistaGen Therapeutics	N/A	-109.72%	-89.62%

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 639.13%. VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 76.84%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

VistaGen Therapeutics has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
VistaGen Therapeutics	$789K	26.98	-$51.42M	-$1.89	N/A

Summary

Biomea Fusion beats VistaGen Therapeutics on 8 of the 14 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Lifevantage?

VistaGen Therapeutics (NASDAQ:VTGN) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

VistaGen Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Lifevantage has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$789K	26.98	-$51.42M	-$1.89	N/A
Lifevantage	$228.53M	0.59	$9.81M	$0.45	23.78

In the previous week, Lifevantage had 3 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Lifevantage and 0 mentions for VistaGen Therapeutics. Lifevantage's average media sentiment score of 0.34 beat VistaGen Therapeutics' score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
Lifevantage	Neutral

VistaGen Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 76.84%. Lifevantage has a consensus target price of $5.00, indicating a potential downside of 53.27%. Given VistaGen Therapeutics' higher probable upside, research analysts plainly believe VistaGen Therapeutics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 22.0% of Lifevantage shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lifevantage has a net margin of 2.94% compared to VistaGen Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Lifevantage	2.94%	23.89%	12.47%

Summary

Lifevantage beats VistaGen Therapeutics on 12 of the 15 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Verrica Pharmaceuticals?

VistaGen Therapeutics (NASDAQ:VTGN) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

VistaGen Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

VistaGen Therapeutics presently has a consensus target price of $0.95, suggesting a potential upside of 76.84%. Verrica Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 142.07%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 2 mentions for Verrica Pharmaceuticals and 0 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 equaled Verrica Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
Verrica Pharmaceuticals	Neutral

Verrica Pharmaceuticals has higher revenue and earnings than VistaGen Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$789K	26.98	-$51.42M	-$1.89	N/A
Verrica Pharmaceuticals	$37.16M	2.77	-$17.89M	-$1.03	N/A

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

VistaGen Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. VistaGen Therapeutics' return on equity of -109.72% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Summary

Verrica Pharmaceuticals beats VistaGen Therapeutics on 10 of the 15 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Promis Neurosciences?

VistaGen Therapeutics (NASDAQ:VTGN) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

VistaGen Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market.

VistaGen Therapeutics currently has a consensus price target of $0.95, suggesting a potential upside of 76.84%. Promis Neurosciences has a consensus price target of $26.50, suggesting a potential upside of 170.41%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

VistaGen Therapeutics' return on equity of -109.72% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Promis Neurosciences	N/A	-237.99%	-151.04%

Promis Neurosciences has lower revenue, but higher earnings than VistaGen Therapeutics. Promis Neurosciences is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$789K	26.98	-$51.42M	-$1.89	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

In the previous week, Promis Neurosciences had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 1 mentions for Promis Neurosciences and 0 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 equaled Promis Neurosciences'average media sentiment score.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
Promis Neurosciences	Neutral

Summary

VistaGen Therapeutics beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

How does VistaGen Therapeutics compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

FitLife Brands has a net margin of 6.64% compared to VistaGen Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
VistaGen Therapeutics	N/A	-109.72%	-89.62%

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 61.4% of FitLife Brands shares are held by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, FitLife Brands had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 2 mentions for FitLife Brands and 0 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 beat FitLife Brands' score of -0.53 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
FitLife Brands	Negative
VistaGen Therapeutics	Neutral

FitLife Brands presently has a consensus target price of $21.50, suggesting a potential upside of 107.33%. VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 76.84%. Given FitLife Brands' stronger consensus rating and higher possible upside, equities research analysts clearly believe FitLife Brands is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

FitLife Brands has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$90.85M	1.07	$6.33M	$0.60	17.28
VistaGen Therapeutics	$789K	26.98	-$51.42M	-$1.89	N/A

FitLife Brands has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Summary

FitLife Brands beats VistaGen Therapeutics on 12 of the 16 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTGN vs. The Competition

Export

Metric	VistaGen Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.28M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-0.28	18.93	23.75	23.75
Price / Sales	26.98	176.22	479.79	84.65
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.22	8.04	10.28	6.78
Net Income	-$51.42M	$23.89M	$3.57B	$337.51M
7 Day Performance	-17.03%	-5.98%	-1.43%	-2.72%
1 Month Performance	-12.01%	2.78%	3.28%	1.86%
1 Year Performance	-77.24%	36.25%	23.37%	26.60%

VistaGen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTGN VistaGen Therapeutics	2.1443 of 5 stars	$0.54 -1.2%	$0.95 +76.8%	-77.0%	$21.28M	$789K	N/A	40	Gap Up
BMEA Biomea Fusion	2.2085 of 5 stars	$1.39 +0.7%	$8.29 +496.1%	-49.0%	$99.77M	N/A	N/A	50	Gap Down
LFVN Lifevantage	2.9927 of 5 stars	$9.43 +19.8%	$5.00 -47.0%	-20.4%	$99.29M	$228.53M	20.96	260	Gap Up High Trading Volume
VRCA Verrica Pharmaceuticals	2.3902 of 5 stars	$5.90 +2.4%	$14.50 +145.8%	-1.2%	$98.95M	$37.16M	N/A	40
PMN Promis Neurosciences	2.5107 of 5 stars	$10.41 -3.7%	$26.50 +154.6%	-23.6%	$96.94M	N/A	N/A	5	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTGN) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. BMEA, LFVN, VRCA, PMN, and FTLF

How does VistaGen Therapeutics compare to Biomea Fusion?

Summary

How does VistaGen Therapeutics compare to Lifevantage?

Summary

How does VistaGen Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does VistaGen Therapeutics compare to Promis Neurosciences?

Summary

How does VistaGen Therapeutics compare to FitLife Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. BMEA, LFVN, VRCA, PMN, and FTLF

How does VistaGen Therapeutics compare to Biomea Fusion?

Which has more volatility & risk, BMEA or VTGN?

Do institutionals & insiders believe in BMEA or VTGN?

Does the media prefer BMEA or VTGN?

Is BMEA or VTGN more profitable?

Do analysts recommend BMEA or VTGN?

Which has better earnings & valuation, BMEA or VTGN?

Summary

How does VistaGen Therapeutics compare to Lifevantage?

Which has more risk and volatility, VTGN or LFVN?

Which has better earnings & valuation, VTGN or LFVN?

Does the media favor VTGN or LFVN?

Do analysts recommend VTGN or LFVN?

Do institutionals & insiders believe in VTGN or LFVN?

Is VTGN or LFVN more profitable?

Summary

How does VistaGen Therapeutics compare to Verrica Pharmaceuticals?

Which has more volatility and risk, VTGN or VRCA?

Do analysts rate VTGN or VRCA?

Does the media favor VTGN or VRCA?

Which has preferable earnings and valuation, VTGN or VRCA?

Do insiders & institutionals have more ownership in VTGN or VRCA?

Is VTGN or VRCA more profitable?

Summary

How does VistaGen Therapeutics compare to Promis Neurosciences?

Do institutionals & insiders hold more shares of VTGN or PMN?

Which has more risk and volatility, VTGN or PMN?

Do analysts recommend VTGN or PMN?

Is VTGN or PMN more profitable?

Which has higher earnings & valuation, VTGN or PMN?

Does the media favor VTGN or PMN?

Summary

How does VistaGen Therapeutics compare to FitLife Brands?

Is FTLF or VTGN more profitable?

Do institutionals and insiders have more ownership in FTLF or VTGN?

Does the media refer more to FTLF or VTGN?

Do analysts prefer FTLF or VTGN?

Which has stronger earnings and valuation, FTLF or VTGN?

Which has more risk and volatility, FTLF or VTGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools